

Short Report

Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival

Miriam Potrony¹, Esther Carreras², Fernando Aranda², Lisa Zimmer³, Joan-Anton Puig-Butille^{4,5}, Gemma Tell-Martí^{1,5}, Noelia Armiger², Antje Sucker³, Pol Giménez-Xavier^{1,5}, Mario Martínez-Florensa², Cristina Carrera^{1,5}, Josep Malvehy^{1,5}, Dirk Schadendorf³, Susana Puig^{1,5} and Francisco Lozano^{2,6,7}

¹Melanoma Unit, Dermatology Department, Hospital Clínic De Barcelona, IDIBAPS, Universitat De Barcelona, Barcelona, Spain

²Grup D'Immunoreceptors Del Sistema Innat I Adaptatiu, Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain

³Department of Dermatology, University Hospital Essen, Essen, Germany & German Cancer Consortium, Heidelberg, Germany

⁴Melanoma Unit, Molecular Biology and Genetics Department, Hospital Clínic De Barcelona, Barcelona, Spain

⁵Centro De Investigación Biomédica En Red En Enfermedades Raras (CIBERER), Valencia, Spain

⁶Department of Immunology, Hospital Clínic De Barcelona, Barcelona, Spain

⁷Department of Cell Biology, Immunology and Neurosciences, School of Medicine, University of Barcelona, Barcelona, Spain

Despite the recent progress in treatment options, malignant melanoma remains a deadly disease. Besides therapy, inherited factors might modulate clinical outcome, explaining in part widely varying survival rates. T-cell effector function regulators on antitumor immune responses could also influence survival. CD5, a T-cell receptor inhibitory molecule, contributes to the modulation of antimelanoma immune responses as deduced from genetically modified mouse models. The *CD5* SNPs rs2241002 (NM_014207.3:c.671C>T, p.Pro224Leu) and rs2229177 (NM_014207.3:c.1412C>T, p.Ala471Val) constitute an ancestral haplotype (Pro224-Ala471) that confers T-cell hyper-responsiveness and worsens clinical autoimmune outcome. The assessment of these SNPs on survival impact from two melanoma patient cohorts (Barcelona, *N* = 493 and Essen, *N* = 215) reveals that p.Ala471 correlates with a better outcome (OR = 0.57, 95% CI = 0.33–0.99, Adj. *p* = 0.043, in Barcelona OR = 0.63, 95% CI = 0.40–1.01, Adj. *p* = 0.051, in Essen). While, p.Leu224 was associated with increased melanoma-associated mortality in both cohorts (OR = 1.87, 95% CI = 1.07–3.24, Adj. *p* = 0.030 in Barcelona and OR = 1.84, 95% CI = 1.04–3.26, Adj. *p* = 0.037, in Essen). Furthermore survival analyses showed that the Pro224-Ala471 haplotype in homozygosis improved melanoma survival in the entire set of patients (HR = 0.27, 95% CI 0.11–0.67, Adj. *p* = 0.005). These findings highlight the relevance of genetic variability in immune-related genes for clinical outcome in melanoma.

Additional Supporting Information may be found in the online version of this article.

M.P., E.C., D.S., S.P. and F.L. contributed equally to this work.

S.P. and F.L. are senior co-authors of this work.

Conflicts of interest: FL is ad honorem scientific advisor at ImmunNovative Developments and inventor of patent EP11382172.2 “New compounds derived from scavenger-like lymphocyte receptors for use in immunotherapy” related to the present work. LZ has served on the advisory boards and received honoraria and travel support from BMS, MSD and Novartis.

Grant sponsor: Spanish Fondo de Investigaciones Sanitarias; **Grant numbers:** 12/00840, 15/00716; **Grant sponsor:** CIBER de Enfermedades Raras of the Instituto de Salud Carlos III (ISCIII), Spain, co-financed by European Development Regional Fund “A way to achieve Europe” ERDF; **Grant sponsor:** AGAUR of the Catalan Government, Spain; **Grant number:** 2014_SGR_603; **Grant sponsor:** European Commission under the 6th Framework Programme; **Grant number:** LSHC-CT-2006–018702 (GenoMEL); **Grant sponsor:** European Commission under the 7th Framework Programme, Diagnostix; **Grant sponsor:** The National Cancer Institute (NCI) of the US National Institute of Health (NIH); **Grant number:** CA83115; **Grant sponsor:** Fundació La Marató de TV3, Catalonia, Spain; **Grant number:** 201331-30; **Grant sponsor:** Instituto de Salud Carlos III, Spain; **Grant number:** FI14/00231 (PFIS); **Grant sponsor:** Sara Borrell fellowship from Instituto de Salud Carlos III, Spain; **Grant number:** CD15/00016; **Grant sponsor:** Worldwide Cancer Research; **Grant number:** 14-1275; **Grant sponsor:** Fundació La Marató TV3; **Grant number:** 201319-30; **Grant sponsor:** Spanish Ministerio de Economía y Competitividad (Plan Nacional I + D+i, SAF2013–46151-R) co-financed by European Development Regional Fund “A way to achieve Europe” ERDF

DOI: 10.1002/ijc.30184

History: Received 11 Feb 2016; Accepted 2 May 2016; Online 11 May 2016

Correspondence to: Dr. Susana Puig, Melanoma Unit, Dermatology Department, Hospital Clínic De Barcelona, IDIBAPS, Universitat De Barcelona, Barcelona, Spain, Tel.: +[34-932275400], Fax: +[34-932275402], E-mail: susipuig@gmail.com or Dr. Francisco Lozano, Immunology Departments Hospital Clinic, C/Villarroel170, 08036 Barcelona, Spain, Tel.: +[34-932275400], Fax: +[34-932275402]. E-mail: flozano@clinic.ub.es

What's new?

Accumulating clinical and experimental evidence indicates that the T-cell modulatory properties of CD5 might play a role in the antitumor immune response by acting as a putative immune regulator checkpoint. Here, the authors examined the association between *CD5* allelic variations at SNPs rs2229177 and rs2241002 and clinical outcome of malignant melanoma in two independent cohorts. They found that *CD5* functional variants influence melanoma outcome, illustrating the contribution of the genetic variability of the host's immune response on patient survival prospects. This study supports the CD5 immune checkpoint as a new target for the improvement and development of new cancer immunotherapies.

Melanoma is the most deadly of the common skin cancers in Caucasians. To date, histological features of the primary melanoma are important hallmarks of early melanoma prognosis and staging.¹ However, patients within the same tumor stage exhibit a high variation in survival rates suggesting that other intrinsic factors modulate outcome.² Melanoma is highly immunogenic, but can evade immune responses *via* several mechanisms including loss of expression of Class I major histocompatibility complex antigens, production of immunosuppressive cytokines, activation of regulatory T-cells and expression of inhibitors for effector T cells (CTLA-4, PD-1/PD-L1).³ Progress in understanding the relationship between immune and tumor cells has led to the development of successful immunotherapies targeting the so called immune checkpoints (*e.g.*, CTLA-4, PD-L1 and PD-1 inhibitors).⁴ Unfortunately, not all patients respond to these therapies and duration and effectiveness vary among responders.⁵ Thus, the identification of new therapeutic targets and prognostic biomarkers is essential to further improve patient care.

Accumulating clinical and experimental evidence indicates that the T-cell modulatory properties of CD5 might play a role in the antitumor immune response by acting as a putative immune regulator checkpoint.^{6,7} CD5 is a lymphoid-specific 67 kDa receptor, mainly expressed by all T cells and the small B1 subset involved in the production of polyreactive natural antibodies.⁸ Even though the nature of the CD5 ligand is still a controversial matter, it is widely accepted that CD5 is indeed a negative regulator of signaling by the clonotypic antigen-specific receptor present on T and B1 cells^{9,10} to which it physically associates and co-localizes at the center of the immune synapse.¹¹ Noteworthy, CD5 is found to be up-regulated in T and B cells with regulatory/suppressor function as well as in T (either CD4+ or CD8+) and B cells energized by repeated antigen stimulation.^{7,8}

No CD5 deficiencies have been reported in humans so far. However, several coding nonsynonymous single nucleotide polymorphisms (SNP) have been identified in the *CD5* gene.¹² Interestingly, the *CD5* gene has been under recent evolutive selective pressure, probably long after the first colonization of East Asia by anatomically modern humans, the nonsynonymous SNP rs2229177 (NM_014207.3:c.1412C > T), coding for an Ala to Val substitution at the cytoplasmic tail of CD5 (p.Ala471Val), being the most probable target for selection. The rs2229177 variants together with another fre-

quent SNP coding for a Pro to Leu substitution at the extracellular region of CD5 (rs2241002, NM_014207.3:c.671C > T, p.Pro224Leu) constitute different haplotypes, one of which (Pro224-Val471) has been positively selected in East Asian populations.¹² Functional analyses reveal that homozygous carriers of the ancestral Pro224-Ala471 (CC) haplotype present higher *in vitro* T cell proliferative responses and a more severe clinical form of Systemic Lupus Erythematosus compared to homozygous individuals for the more recently derived Pro224-Val471 (CT) haplotype.¹³ This finding suggests a link between differential regulation of T-cell signaling by CD5 variants and distinct autoimmune disease outcome.

Considering that the immune system plays an opposite role in autoimmune diseases and cancer, we addressed the putative association between *CD5* allelic variations at SNPs rs2229177 and rs2241002 and clinical outcome of melanoma in two independent cohorts (Barcelona *N* = 493 and Essen *N* = 215).

Material and Methods**Design and samples**

The retrospective study comprised two independent Hospital Based series of melanoma patients. Recruitment (and therefore blood sampling) took place wherever possible 3–6 months after diagnosis. Patients were included in the study when the following information was available: confirmed alive/death status at last follow-up (melanoma-specific survival), at least one update in follow-up (months) since the date of diagnosis, sentinel lymph node biopsy result (SLN) (positive/negative), gender (male, female), age at diagnosis and Breslow thickness (mm). Exclusion criteria were lack of germinal DNA sample or lack of signed informed consent.

The first set consisted of a Hospital Based series of 493 melanoma patients from the Melanoma Unit of Hospital Clinic of Barcelona, Spain. Patients were diagnosed with melanoma between 1994 and January 2013 (median time of follow-up: 43 months). Cohort disease status was established through the annual review and review of medical notes, from electronic records of the patients with visits every 3–4 months the first 2 years, every 6 months until 5 years and annual until 10 years.

The second cohort comprised a Hospital Based series of 215 melanoma patients from University Hospital Essen, Germany. Patients were diagnosed with melanoma between 1982

and 2009 (median time of follow-up was 46 months). The cohort disease status was established in the same way as for the Barcelona cohort and included an update of lost to follow-up by phone calls.

In the Barcelona cohort, the patient's stage at diagnosis according to AJCC¹ was: 45% Stage I (22 IA, 187 IB, 13 I unknown ulceration status), 33% Stage II (50 IIA, 53 IIB, 17 IIC, 43 II unknown ulceration status) and 22% Stage III (number of positive SLN or presence of micro/macro metastasis was not recorded in our database, thus patients could not be subclassified into IIIA, IIIB or IIIC). In the Essen cohort, the patient's stage at diagnosis according to AJCC was: 28% Stage I (61 IB), 45% Stage II (40 IIA, 33 IIB, 11 IIC, 12 II unknown ulceration status) and 27% Stage III (24 IIIA, 16 IIIB, 5 IIIC, 13 III with unknown number of positive SLN or presence of micro/macro metastasis). The study was approved by the ethical committee of the Hospital Clinic of Barcelona. The patients gave their written, informed consent.

CD5 genotyping

Genomic DNA was obtained from peripheral blood lymphocytes. TaqMan Genotyping Assays were used to genotype *CD5* SNPs rs2229177 (assay number: C__3237272_10) and rs2241002 (assay number: C__25472293_20) according to the manufacturer's recommendations (TermoFisher, Barcelona, Spain). The 7900HT Fast Real-Time PCR System (Applied Biosystems, Bleiswijk, The Netherlands) was used. The results were analyzed using the Applied Biosystems TaqMan Genotyper Software (TermoFisher, Barcelona, Spain).

In the Barcelona set, SNP genotyping was successful for rs2229177 and rs2241002 in 99.4% (490/493) and 99.8% (492/493) of patients, respectively. In Essen, both SNPs were successfully genotyped in 99.5% (214/215) of patients. In the two patient sets both SNPs were in Hardy–Weinberg equilibrium (Barcelona: rs2229177 $p = 0.500$ and rs2241002 $p = 1.000$, Essen: rs2229177 $p = 1.000$ and rs2241002 $p = 0.370$). The two *CD5* SNPs analyzed were not in linkage disequilibrium in either patient set ($D' = 0.597$, $r^2 = 0.100$ and $D' = 0.311$, $r^2 = 0.018$ in Barcelona and Essen, respectively).

Statistical analyses

The main clinical event assessed was melanoma-specific survival. A two-sided Pearson chi-squared test was used for general descriptive analyses for categorical variables. A t test was used for general descriptive analyses for continuous variables. The Breslow thickness variable did not follow the normal distribution and was transformed using the logarithm function. The melanoma-specific survival according to different haplotypes was assessed using Kaplan–Meier curves and backward multivariate Cox regression analysis. The hazard ratio (HR) and its 95% CI were calculated. SPSS 17.0 was used to perform descriptive statistical analyses and survival analyses. Genotype and haplotype association analyses were performed using the bioinformatics tool SNPStats ([\[logia.net/SNPstats\]\(http://logia.net/SNPstats\)\).¹⁴ The odds ratio \(OR\) and its 95% CI were calculated. Gender, SLN, age at diagnosis and log transformed Breslow were included as covariates in the analyses. Information about Ulceration was not included due to the high number of tumors without this information in the Barcelona set of patients. The tests were considered significant if \$p\$ values or adjusted \$p\$ values as applicable was \$<0.05\$.](http://bioinfo.iconco-</p>
</div>
<div data-bbox=)

Results and Discussion

Descriptive analyses of the clinical and genetic variables showed that the characteristics known to be associated with worse melanoma prognosis (male gender, melanoma-death and positive sentinel lymph node) and rs2241002 genotype frequencies were significantly different between the two cohorts (Supporting Information Tables S1 and S2). The association analysis of SNP rs2229177 with melanoma-specific survival (Table 1) showed that the ancestral C allele (p.Ala471) had a statistically significant effect on melanoma outcome in the Barcelona-cohort (OR = 0.57, 95% CI = 0.33–0.99, Adj. $p = 0.043$) and a trend close to statistical significance in the Essen-cohort (OR = 0.63, 95% CI = 0.40–1.01, adj. $p = 0.051$). Additionally, the minor T allele of rs2241002 (p.Leu224) was associated with increased melanoma-associated mortality in both the Barcelona-cohort (OR = 1.87, 95% CI = 1.07–3.24, Adj. $p = 0.030$) and the Essen-cohort (OR = 1.84, 95% CI = 1.04–3.26, Adj. $p = 0.037$).

Haplotype analyses with SNPStats showed that the presence of T alleles for both SNPs (Leu224-Val471 haplotype) was associated with increased risk of melanoma-associated death in the Barcelona-cohort (OR = 2.52, 95% CI = 1.22–5.22, Adj. $p = 0.013$), while in Essen, the presence of the C allele in both SNPs (Pro224-Ala471 haplotype) had a protective role on melanoma survival (OR = 0.49, 95% CI = 0.27–0.90, Adj. $p = 0.022$). Thus, the ancestral *CD5* Pro224-Ala471 haplotype associates with increased melanoma-specific survival, while the more recently derived Leu224-Val471 associates with reduced melanoma survival. As functional analyses have revealed that the ancestral *CD5* Pro224-Ala471 haplotype increases the immune activity compared with the Pro224-Val471 haplotype,¹³ we assessed the melanoma-specific survival using Kaplan–Meier and Cox regression analyses, comparing individuals homozygous for each haplotype in the entire patient set (Fig. 1a). We identified that carriers of the Pro224-Ala471 haplotype in homozygosis have a better survival compared with the carriers of the Pro224-Val471 haplotype in homozygosis (HR = 0.21, 95% CI 0.07–0.58, Adj. $p = 0.003$). These individuals also have a better survival compared with other haplotype combinations (HR = 0.27, 95% CI 0.11–0.67, Adj. $p = 0.005$) and also compared with homozygotes for the Leu224-Val471 haplotype (HR = 0.20, 95% CI 0.05–0.80, Adj. $p = 0.022$), the most extreme haplotype combination (Fig. 1b). When AJCC staging was included in the model instead of log transformed Breslow and SLN status, the results were similarly significant (data not shown).

Table 1. Genetic association of the CD5 SNPs rs2229177 and rs2241002 with melanoma-specific survival

	rs2229177 (p.Ala471Val)									OR	95% CI	Adj. P^1
	MAF (C allele)		Genotype Frequency									
	Alive	Dead	Alive			Dead						
			CC	CT	TT	CC	CT	TT				
Barcelona (N = 490)	0.48	0.36	0.24	0.48	0.28	0.12	0.47	0.41	0.57	0.33, 0.99	0.043	
Essen (N = 214)	0.48	0.41	0.24	0.49	0.27	0.14	0.53	0.33	0.63	0.40, 1.01	0.051	

	rs2241002 (p.Pro224Leu)									OR	95% CI	Adj. P^1
	MAF (T allele)		Genotype Frequency									
	Alive	Dead	Alive			Dead						
			CC	CT	TT	CC	CT	TT				
Barcelona (N = 492)	0.23	0.34	0.59	0.36	0.05	0.47	0.37	0.16	1.87	1.07, 3.24	0.030	
Essen (N = 214)	0.16	0.25	0.71	0.27	0.02	0.54	0.42	0.04	1.84	1.04, 3.26	0.037	

The median (range) time of follow-up in months for Barcelona alive and death patients was 42 (1–217) and 44 (3–124), respectively, and for Essen alive and death patients was 48 (1–177) and 38 (8–244), respectively.

MAF: minor allele frequency; OR: Odds Ratio

Minor allele of rs2229177 SNP was C, while minor allele of rs2241002 was T.

The genetic model used was the log-additive.

The statistically significant results are highlighted in bold.

¹ p -values were adjusted by age at diagnosis, gender, log transformed Breslow and sentinel lymph node biopsy result (positive/negative).

As patients from different stages at diagnosis (I, II and III) were included in the study, we performed survival analyses according to the functional Pro224-Ala471 vs. Pro224-Val471 haplotypes, grouping patients by staging (Supporting Information Fig. S1). Although, we have not enough power to reach significance, a protective effect on melanoma survival of the Pro224-Ala471 haplotype in homozygosis could be observed in the three stages (Stage I: HR = 0.18, 95% CI 0.21–1.53, Adj p = 0.117; Stage II: HR = 0.15, 95% CI 0.02–1.22, Adj p = 0.077, and Stage III: HR = 0.39, 95% CI 0.11–1.43, Adj p = 0.154). Thus, the effect of CD5 variants on the modulation of melanoma outcome is independent of the stage at diagnosis.

The results represent, as far as we know, the first report on the impact of functional germline variants from an immune-regulatory receptor in melanoma outcome. Previous studies have identified SNPs from several non-immune related genes that impact melanoma prognosis. This is the case for the GC gene (rs2282679), linking lower serum levels of vitamin D with increased melanoma-specific deaths,¹⁵ and for the MC1R gene,¹⁶ for which loss of function variants up-regulate oxidative stress-related pathways and DNA damage,¹⁷ favoring the apoptosis of damaged cells. SNPs in Nucleotide Excision Repair (NER) and Poly [ADP-Ribose] Polymerase 1 (PARP1) genes have also been implicated in melanoma prognosis, showing the relevance of the DNA damage and repair system for tumor survival.^{18,19} A similar situation applies to genes from the Hippo pathway, which control cell migration, development and organ sizes in diverse species,²⁰ as well as genes from the Notch²¹ and Fanconi anemia²² pathways. Related with immunity, SNPs in the interleukin locus and angiogenesis have also been associated with melanoma progression.^{23,24}

The presence of immune cells in the tumor microenvironment is known to influence melanoma prognosis.²⁵ Currently available melanoma immunotherapies target lymphocyte receptors involved in down-regulating T-cell effector functions (e.g., CTLA-4, PD-1 and PD-1 ligand), collectively known as “immune check-points.” In accordance with previously published studies,⁷ the present association study supports a role for CD5 as a new immune modulatory receptor, which paves the way for improvement of current therapies against melanoma. Indeed, available evidence supports the involvement of CD5 in the regulation of antitumor immune responses. Early mouse studies showed the efficacy of a non-depleting anti-CD5 monoclonal against lymphoid and non-lymphoid tumors.²⁶ Later reports found that *in situ* sensory adaptation of Tumor infiltrate lymphocytes (TILs) from patients undergoing lung carcinoma involves down-regulation in CD5 surface expression.⁶ More recently, studies involving CD5-deficient mice⁶ and transgenic mice expressing a soluble form of human CD5²⁷ showed improved anti-tumor responses using non-orthotopic mouse melanoma models (B16 cells).

In conclusion, the present study illustrates an unprecedented, although predictable, fact: the genetic variability of the host's immune response influences melanoma survival. The results are also in line with a recent observation from our group showing that rs2229177 variants impact the survival response of chronic lymphocytic leukemia patients to conventional chemotherapy regimens.²⁸ Thus, the identification of new inherited variants in immune-related genes may also be useful to identify patients that are going to respond better to available treatments.




Figure 1. Melanoma-specific survival curve according to the genetic status of *CD5*. (a) Melanoma-free survival curve in patients homozygous for the Pro224-Ala471 haplotype (dark gray) vs. Pro224-Val471 (light gray). HR comparing homozygous Pro224-Ala471 with homozygous Pro224-Val471 was 0.21 (95% CI 0.07–0.58), Adj. $p = 0.003$. The 5-year survival rate was 0.96 for Pro224-Ala471 homozygous and 0.77 for Pro224-Val471 homozygous. HR and p -values were adjusted by age at diagnosis, gender, log transformed Breslow and SLN biopsy result (positive/negative). (b) Melanoma-free survival curve in patients homozygous for the Pro224-Ala471 haplotype (dark gray) vs. Leu224-Val471 homozygous (light gray) vs. other haplotype combination (gray) (Log-rank test $p = 0.010$). HR comparing homozygous Pro224-Ala471 with other was 0.27 (95% CI 0.11–0.67), Adj. $p = 0.005$. HR comparing homozygous Leu224-Val471 with other was 1.22 (95% CI 0.44–3.36), Adj. $p = 0.703$. HR comparing homozygous Pro224-Ala471 with homozygous Leu224-Val471 was 0.20 (95% CI 0.05–0.80), Adj. $P = 0.022$. The 5-year survival rate was 0.96 for Pro224-Ala471 homozygous, 0.82 for other haplotype combination and 0.66 for Leu224-Val471 homozygous. HR and p -values were adjusted by age at diagnosis, gender, log transformed Breslow and SLN biopsy result (positive/negative).

Acknowledgements

The authors are indebted to Elena Bosch for helpful critical comments. The work was carried out at the Esther Koplowitz Center, Barcelona. Miriam

Potrony is the recipient of a PhD Fellowship FI14/00231 (PFIS) from Instituto de Salud Carlos III, Spain. Fernando Aranda is supported by Sara Borrell fellowship CD15/00016 from Instituto de Salud Carlos III, Spain.

References

- Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009;27:6199–206.
- Schramm SJ, Mann GJ. Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. *Mol Cancer Ther* 2011;10:1520–8.
- Töpfer K, Kempe S, Müller N, et al. Tumor evasion from T cell surveillance. *J Biomed Biotechnol* 2011;2011:918471–19.
- La-Beck NM, Jean GW, Huynh C, et al. Immune checkpoint inhibitors: new insights and current place in cancer therapy. *Pharmacotherapy* 2015;35:963–76.
- Marquez-Rodas I, Cerezuela P, Soria A, et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. *Ann Transl Med* 2015;3:267.
- Tabbekh M, Mokrani-Hammani M, Bismuth G, et al. T-cell modulatory properties of CD5 and its role in antitumor immune responses. *Oncotarget* 2013;2:e22841.
- Consuegra-Fernandez M, Aranda F, Simoes I, et al. CD5 as a target for immune-based therapies. *Crit Rev Immunol* 2015;35:85–115.
- Soldevila G, Raman C, Lozano F. The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. *Curr Opin Immunol* 2011;23:310–18.
- Tarakhovskiy A, Kanner SB, Hombach J, et al. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. *Science* 1995;269:535–7.
- Bikah G, Carey J, Ciallella JR, et al. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. *Science* 1996;274:1906–9.
- Brossard C, Semichon M, Trautmann A, et al. CD5 inhibits signaling at the immunological synapse without impairing its formation. *J Immunol* 2003;170:4623–9.
- Carnero-Montoro E, Bonet L, Engelken J, et al. Evolutionary and functional evidence for positive selection at the human CD5 immune receptor gene. *Mol Biol Evol* 2012;29:811–23.
- Cenit MC, Martínez-Florensa M, Consuegra M, et al. Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients. *PLoS One* 2014;9:e113090.
- Sole X, Guino E, Valls J, et al. SNPStats: a web tool for the analysis of association studies. *Bioinformatics* 2006;22:1928–9.
- Davies JR, Field S, Randerson-Moor J, et al. An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. *Pigm Cell Melanoma Res* 2014;27:234–43.
- Davies JR, Randerson-Moor J, Kukulicz K, et al. Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. *Pigm Cell Melanoma Res* 2012;25:384–94.
- Puig-Butille JA, Escamez MJ, Garcia-Garcia F, et al. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. *Oncotarget* 2014;5:1439–51.

18. Davies JR, Jewell R, Affleck P, et al. Inherited variation in the PARP1 gene and survival from melanoma. *Int J Cancer* 2014;135:1625–33.
19. Li C, Yin M, Wang LE, et al. Polymorphisms of nucleotide excision repair genes predict melanoma survival. *J Invest Dermatol* 2013;133:1813–21.
20. Yuan H, Liu H, Liu Z, et al. Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival. *Int J Cancer* 2015;137:638–45.
21. Zhang W, Liu H, Liu Z, et al. Functional variants in notch pathway genes NCOR2, NCSTN, and MAML2 predict survival of patients with cutaneous melanoma. *Cancer Epidemiol Biomarkers Prev* 2015;24:1101–10.
22. Yin J, Liu H, Liu Z, et al. Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. *J Invest Dermatol* 2015;135:542–50.
23. Park JY, Amankwah EK, Anic GM, et al. Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. *Cancer Epidemiol Biomarkers Prev* 2015;22: 827–34.
24. Rendleman J, Vogelsang M, Bapodra A, et al. Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. *J Med Genet* 2015;52:231–9.
25. Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. *J Clin Oncol* 2013;31:4252–9.
26. Hollander N. Immunotherapy of lymphoid and nonlymphoid tumors with monoclonal anti-Lyt-1 antibodies. *J Immunol* 1984;133:2801–5.
27. Fenutría R, Martínez VG, Simoes I, et al. Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses. *PLoS One* 2014;9: e84895.
28. Delgado J, Bielig T, Bonet L, et al. Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. *Br J Haematol* 2016. doi:10.1111/bjh14037.